ResMed RMD Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $32.12M-2.6% | $32.96M+8.4% | $30.4M-68.7% | $97.25M-38.0% | ||
| $3.64M— | —— | -$7.27M+14.4% | -$8.49M+24.3% | ||
| -$10.3M-155% | -$4.05M— | —— | -$12.2M-184% | ||
| $1.4B+37.2% | $1.02B+13.7% | $897.56M+15.2% | $779.44M+64.3% | ||
| -$10.3M-155% | -$4.05M— | —— | -$12.2M— | ||
| $45.27M-2.7% | $46.52M+10.7% | $42.02M+35.2% | $31.08M0.0% | ||
| $4.11M+109% | -$45.71M+3.5% | -$47.38M-112% | -$22.31M— | ||
| $0— | $0-100% | $20.23M— | $0— | ||
| —— | $278.4M+28.4% | $216.87M-54.6% | $478.12M+116% | ||
| $90.96M-25.5% | $122.07M+289% | $31.34M— | —— | ||
| $76.68M-42.9% | $134.28M+26.1% | $106.51M— | —— | ||
| —— | -$172.2M-168% | $255.09M-18.2% | $311.68M— | ||
| -$82.63M-172% | $115.21M-16.6% | $138.13M-17.8% | $168.11M+189% | ||
| $28.48M-37.7% | $45.71M-3.5% | $47.38M+179% | $16.95M-29.3% | ||
| -$606.25M+45.8% | -$1.12B— | —— | —— | ||
| -$200.05M+25.8% | -$269.78M+76.7% | -$1.16B-404% | -$229.92M-45.1% | ||
| $1.75B+25.0% | $1.4B+102% | $693.3M+97.4% | $351.15M-52.3% | ||
| $6.28M-18.4% | $7.7M— | —— | $4.67M+203% | ||
| $300.03M+100% | $150.01M— | —— | $0— | ||
| $310.88M+10.1% | $282.32M+9.3% | $258.28M+5.3% | $245.34M+8.2% | ||
| $140.1M+4.0% | $134.76M-86.7% | $1.02B+2,273% | $42.78M— | ||
| $139.25M+4.3% | $133.46M-86.8% | $1.01B+2,267% | $42.78M— | ||
| $10.78M-30.0% | $15.4M+7.5% | $14.33M-32.4% | $21.2M+50.2% | ||
| $6.42M-49.7% | $12.77M-60.4% | $32.23M+55.5% | $20.72M-4.9% | ||
| $89.87M-9.6% | $99.46M-16.9% | $119.67M-11.2% | $134.84M+31.3% | ||
| $74.44M+40.2% | $53.09M+8.0% | $49.14M+3.7% | $47.38M+25.4% | ||
| $40M-95.2% | $835M+106% | $405M+144% | $166M-72.9% | ||
| $91.66M+14.3% | $80.18M+12.7% | $71.14M+9.0% | $65.26M+2.1% | ||
| $1.88B+25.9% | $1.5B+15.4% | $1.3B+11.8% | $1.16B+9.4% | ||
| $1.69B+27.7% | $1.32B+16.6% | $1.13B+13.2% | $1B+10.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ResMed's revenue?
- ResMed (RMD) generated $5.5B in revenue over the trailing twelve months, up 10.3% year over year.
- Is ResMed profitable?
- ResMed reported $1.5B in net income over the trailing twelve months, a 27.4% net margin.
- What are ResMed's profit margins?
- Gross margin is 61.6% and operating margin is 34.2%, with a 27.4% net margin.
- What is ResMed's earnings per share?
- ResMed's diluted EPS over the trailing twelve months is $10.37.
- Where does ResMed's income statement data come from?
- Every line is extracted from ResMed's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
